Trinity Biotech Secures Key Regulatory Approval for Offshored and Outsourced Manufacturing of Its Flagship Rapid HIV Test, Accelerating Strategic & Financial Performance Transformation
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 24 2025
0mins
Source: Globenewswire
WHO Approval for Outsourced Manufacturing: Trinity Biotech has received World Health Organization approval to transition the upstream manufacturing of its TrinScreen™ HIV rapid test to an outsourced model, aiming to enhance cost efficiency and scalability while maintaining product integrity.
Strategic Transformation Goals: This move is part of a broader strategy to reduce fixed costs, improve gross margins, and support sustainable growth, with implementation expected in Q3 2025.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
